José Baselga, MD, PhD
Trastuzumab deruxtecan (Enhertu) improved overall survival (OS) versus chemotherapy in patients with heavily pretreated unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer, according to topline findings from the phase II DESTINY-Gastric01 trial.1
- Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint [news release]. AstraZeneca; January 27, 2020. bit.ly/37HPmG1. Accessed January 27, 2020.
- Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9.
... to read the full story